Online-Symposium „Proteases in SARS-CoV2 Infections“
Freiburg, Jan 11, 2022
Inhibiting proteolytic enzymes (Proteases) is one means of counteracting viral infections, including SARS2 CoV2 invasion and the COVID-19 pandemic. Among others, the drug Paxlovid, just approved in the U.S., is based on this medical technology, which is also used in HIV treatment. On Jan. 20, 2022 (5 p.m.), the international online symposium "Proteases in SARS-CoV2 Infections" will address the latest findings in protease research and the development of corresponding agents against SARS-CoV2. The symposium is organized digitally via ZOOM by the Research Training Group 2606 "Protpath: Structured Doctoral Training in Proteolysis" of the University of Freiburg together with the International Proteolysis Society (IPS). Co-chairs of the symposium are IPS Vice President Dr. Ruth Geiss-Friedlander from the University of Freiburg and IPS President Dr. Anthony O'Donoghue from the University of California.
Presenters are: Prof. Dr. Rolf Hilgenfeld (University of Lübeck), Prof. Dr. Joanne Lemieux (University of Alberta), Wioletta Rut (Wrocław University of Technology), Isabel Pablos (University of British Columbia), James Janetka (Washington University) and Georg Jocher (German Center for Neurodegenerative Diseases in Munich).
- What: Symposium
- When: 20.01.2022, 5 p.m.
- Where: Online via ZOOM
- The event is addressed to media members.
-
Registration is required via info@pr.uni-freiburg.de. Registered participants will receive the registration data for the ZOOM conference via mail.
-
More information about the IPS: https://www.protease.org/
- Event organizer: Research Training Group 2606 „Protpath: Structured Doctoral Training in Proteolysis" of the University of Freiburg, International Proteolysis Society (IPS)
- Contact: Dr. Ruth Geiss-Friedlander, Tel.: 0761/203-9615, E-Mail: ruth.geiss-friedlander@mol-med.uni-freiburg.de
- The event will be held in English.
- Further information about IPS: https://www.protease.org/